IntroductionB-cell lymphoma, a malignant proliferative disease originating from lymphoid tissue, poses a grave threat to human health. CD20 has emerged as a promising target for lymphoma treatment. However, due to the significant heterogeneity of B-cell lymphomas, conventional CD20 monoclonal antibodies show limited penetration, severely impeding the progress of B-cell lymphoma therapies.MethodsIn contrast, single-domain antibody molecules derived from cartilaginous fish have a molecular weight as small as 12 kDa, granting them robust penetration capabilities and making them the smallest known molecules of efficiently targeting specific antigens.ResultsAs a result, these molecules hold tremendous potential as candidate drugs for lymphoma treatment. In this study, the whitespotted bamboo shark (Chiloscyllium plagiosum) was immunized with recombinant human CD20 to generate specific single-domain antibodies (sdAbs) targeting CD20. By utilizing phage display technology, the variable new antigen receptors (VNARs) were successfully screened and identified, and play an important role in the inhibition of Raji lymphoblastoma.DiscussionThe sdAbs obtained through this research represent promising candidates for B-cell lymphoma treatment, displaying significant potential for clinical applications and offering a new direction for the development of targeted therapies against lymphoma.

中文翻译：

---

前沿 |Chiloscyllium plagiosum 抗 CD20 VNAR 的筛查和抗 Raji 淋巴瘤作用


引言B 细胞淋巴瘤是一种起源于淋巴组织的恶性增殖性疾病，对人类健康构成严重威胁。CD20 已成为淋巴瘤治疗的有前途的靶点。然而，由于 B 细胞淋巴瘤的显著异质性，常规 CD20 单克隆抗体的渗透性有限，严重阻碍了 B 细胞淋巴瘤治疗的进展。方法相比之下，源自软骨鱼的单域抗体分子的分子量低至 12 kDa，赋予了它们强大的渗透能力，并使它们成为已知有效靶向特定抗原的最小分子。结果因此，这些分子作为淋巴瘤治疗的候选药物具有巨大的潜力。在本研究中，用重组人 CD20 免疫白斑竹鲨 （Chiloscyllium plagiosum），以产生靶向 CD20 的特异性单域抗体 （sdAbs）。利用噬菌体展示技术，成功筛选鉴定了可变新抗原受体 （VNARs），并在抑制 Raji 淋巴母细胞瘤中发挥重要作用。讨论通过这项研究获得的 sdAb 代表了 B 细胞淋巴瘤治疗的有前途的候选者，显示出巨大的临床应用潜力，并为淋巴瘤靶向疗法的开发提供了新的方向。